Phase I study of sorafenib in patients with refractory or relapsed acute leukemias - Wikidata - wikimedia - TriplyDB

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

http://www.wikidata.org/entity/Q34451540

about

Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.'Acute myeloid leukemia: a comprehensive review and 2016 update'Secondary mutations as mediators of resistance to targeted therapy in leukemia Phase II study of sorafenib in patients with relapsed or refractory lymphoma.Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant The Future of Targeting FLT3 Activation in AML.Gene mutations and molecularly targeted therapies in acute myeloid leukemia.FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12.Monitoring chemotherapeutic response by hyperpolarized 13C-fumarate MRS and diffusion MRI.Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review Targeting oncogenic Ras signaling in hematologic malignancies.The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.Is targeted therapy feasible in acute myelogenous leukemia?The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells Acute myeloid leukemia: advancing clinical trials and promising therapeutics.Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study.Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants How I treat FLT3-mutated AML.TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia.Sorafenib Induced Hand Foot Skin Rash in FLT3 ITD Mutated Acute Myeloid Leukemia-A Case Report and Review of Literature.Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.The role of quizartinib in the treatment of acute myeloid leukemia.

P2860

Q26749870-2652CBEE-133D-4326-93FE-EEEB21B17F44 Q27852520-CB554FB6-67DF-4C1F-A616-34DCC17E641C Q28072539-02E209D9-59D9-4FDD-AA50-5068D53AFCB1 Q28087213-36E012CB-0F3F-44BD-942F-9DB3D0A3090C Q33401136-052E10E3-8196-4832-BA9E-486E93C7FD93 Q33442949-D4DB3170-206C-4DF4-89C5-4A0256FB1B50 Q33772438-6CDA7BA7-7C4D-4335-9BD3-B17379F491E6 Q33882022-271578BD-2B6D-4E9D-B1FD-FCCDE1EA87B4 Q33903030-8DFE9F8A-EB20-4312-AC0E-02301F3E88EC Q33943277-50D213EC-3350-4CD8-9878-6C0A4C143DE7 Q34004131-8F5BE53B-27ED-469B-95B0-84902FC3FC81 Q34011740-755235FE-D6DF-417C-8DFB-ADA953E67047 Q34088370-F0FC1D83-FB57-4E6F-8E69-2EF0BC438DA0 Q34555386-DB68CC01-779B-4D7E-965B-70FBADD52272 Q34647741-EB302A06-2EA2-4A58-87AA-0A6E9C900E6D Q34993145-21BBD4E9-2A4A-4F9B-ABB5-3FDA685338A7 Q35172210-F7F13EC1-D2B4-4C7C-8BD6-BEE85214D110 Q35224437-48FED711-6669-4F22-A418-EA02A3D61C11 Q35485832-6159A336-119D-4DC7-BB79-B511BA2B74B2 Q35703167-24C7DD17-8590-435E-8CD6-103868CB25E3 Q35740894-65543A5F-DE8F-4504-9FD8-E298C8708F4A Q36270115-B0A06D02-0E4D-4469-A3B1-8236686EF70B Q36352506-029E1850-1722-4F43-B4A3-016CAD82AFDB Q36366626-27992761-12DE-4FF8-A634-9A48877B3238 Q36410157-136DBF48-5CEA-469B-8C38-5A86B106455C Q36416358-59DA851B-03AA-4FC4-B7A7-78100D40C879 Q36693252-5BE48533-EE4B-4E59-8F71-17FA3E02D0F3 Q36892604-275835F1-26CA-4BD5-8C96-87A2F0B74446 Q36907832-05B8EEA8-B88B-4309-A425-2F463D05F137 Q36940606-D3FE68C1-20AF-408A-A45D-68CDEC2D2CFB Q37213049-60CD4F2D-B346-4FEE-B073-EA195489AEE8 Q37221579-E5D32CC1-0E19-46A0-A233-AC070FF3878B Q37399091-06770D20-062D-4F5A-86F5-2E7C52D99074 Q37429734-FB17584F-B09F-4016-AD0E-5E09AEAE4DFD Q37623389-AA4C9C1D-36FF-4EF0-BA7C-6F8A07A771A4 Q37623535-97B3ACD1-F9C2-4AD7-A214-649B25451062 Q37644854-36ECF0B4-906A-4DD8-9A4A-5BDAF9AFD3AD Q37663028-04C34A2E-69FA-4814-8FCD-5911AA55475D Q37865381-6492101B-0AE3-4971-BE62-A7FBA50F549C Q38144189-36576843-CEFC-4F23-B4A3-92F3F68EA235

P2860

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

http://www.wikidata.org/entity/Q34451540

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

@ast

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

@en

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

@nl

type

label

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

@ast

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

@en

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

@nl

prefLabel

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

@ast

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

@en

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

@nl

P1433

Q34451540-A3EB27D3-1414-49DD-80FF-DF08E2855A42

P1476

Q34451540-7A72EC4E-B588-4816-AB5C-87DB42C1C05F

P2093

Q34451540-3DB74C9F-5B30-46F7-AB18-37980C738D9D

Q34451540-909C46ED-D3A4-4287-99D6-5D983F84E0F7

Q34451540-A566073D-B339-4620-B6BD-10B84E1E8FF1

P2860

Q34451540-11809F69-06EC-4236-AB02-157C663768F2

Q34451540-1D57D2A5-503C-4E73-9568-C267C53DC0C3

Q34451540-1E982F85-3567-48BE-B1DC-6D2A6CB23038

Q34451540-261F09F9-C807-4D72-88AC-42FBB7FA86E6

Q34451540-3002289C-12BA-4DED-9FC1-E46507649F70

Q34451540-304C43A7-2AB3-43A1-916D-E665CBFA62B7

Q34451540-315B1835-FFC8-4CD9-812E-DF684541FE82

Q34451540-36C5411A-57BE-4C5F-B115-1DA8FF3A67E6

Q34451540-38A842A4-8367-4CC1-A771-CFE7CDC9BA6D

Q34451540-460A9F4B-2A6A-4BA4-B187-9EDD6AE91612

P304

Q34451540-FE97C38E-E0FA-4F3F-9B67-F49A49C80EB8

P31

Q34451540-ADD327C7-11B6-4BE5-8978-FB477EF715EC

P356

Q34451540-A0EE5F40-08FC-4DFE-86B3-CEA1E2DDB32A

P433

Q34451540-21485F6F-4E60-43C0-AB94-F6413C037C1B

P478

Q34451540-C98EF8CA-03A5-48EE-82ED-A62F3C32AEF0

P50

Q34451540-013BEDDA-E793-45BC-A9AA-02F778259D66

Q34451540-04CCE7F5-E752-4DB8-A49A-CA740E97DC2D

Q34451540-182CDFC6-AB6E-4363-8FA2-839FF78FACF1

Q34451540-539F3CB9-2E35-4027-8283-B0140F5B04F3

Q34451540-6870F32E-B05C-4C66-9E4E-743FCC9340D3

Q34451540-CC1E0C17-8CF7-43A4-9D58-AF0DE134A440

Q34451540-CD2F2C30-61BD-4DF9-BCF9-209051EDBF1A

Q34451540-E40FA86C-2980-435F-954A-C6ABD51C5D68

P577

Q34451540-B741EFC1-A6CC-48BB-8BC7-62F67D1564A4

P5875

Q34451540-76FACC0D-E921-4FD2-BD89-E7BCA37B48A7

P698

Q34451540-AD7C4CB3-BB09-4F8A-9FA0-0D2B23D5151B

P921

Q34451540-623A9F8A-6EFF-4EC5-A60B-1926D5097D60

Q34451540-7250B3F7-7A38-4232-B8EF-7A3E66D7154C

P932

Q34451540-EC78871E-075C-4E5D-886C-0CA23755C182

P356

HAEMATOL.2010.030452

P1433

P1476

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

@en

P2093

John J Wright

http://www.w3.org/2001/XMLSchema#string

Sheela Mathews

http://www.w3.org/2001/XMLSchema#string

Weiguo Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

Raf kinase as a target for anticancer therapeutics

Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia

Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance.

Antitumor activity of sorafenib in FLT3-driven leukemic cells.

The roles of FLT3 in hematopoiesis and leukemia.

P304

62-68

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2010.030452

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P50

Jorge Eduardo Cortes

Hagop Kantarjian

Srdan Verstovsek

Gautam Borthakur

Marina Konopleva

Michael Andreeff

P577

2010-10-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47449796

http://www.w3.org/2001/XMLSchema#string

P698

20952518

http://www.w3.org/2001/XMLSchema#string

P921

P932

3012766

http://www.w3.org/2001/XMLSchema#string